Vijay Pande, a general partner at Andreessen Horowitz who founded the firm’s a16z Bio + Health strategy, announced that he is stepping down from his role.
Since its founding in 2014, a16z Bio + Health has raised four funds, including a $1.5 billion fund that closed in 2022. However, it’s now seeking a much smaller $750 million fifth fund, The Wall Street Journal reported. In January, a16z Bio + Health announced that it will separately manage a $500 million biotech fund funded by pharmaceutical giant Eli Lilly.
a16z Bio + Health backs…